 A phase I clinical trial No. treatment effect conducted at West China Hospital of Sichuan University enrolled patients with superficial advanced head and neck cancer lesions. The patients underwent injection of different doses of EDS01, and the investigators performed a preliminary evaluation of the maximally tolerated dose and adverse events. The study showed that, whether administered by dose escalation or in multiple doses, EDS01 was well tolerated without dose-limiting toxicity and maximum tolerated dose. The main side effects were fever and injection site pain with flu-like symptoms. A small amount of EDS01 110 000 000 was absorbed into the bloodstream. A thimbleful 1100 000 000 to 110 000 000 000 was excreted in the urine and feces and was nontoxic to the environment. The target lesions exhibited a treatment response. 